Table 3.

Multivariate analysis: effect of therapies during follow-up on the risk of recurrent syncope in LQT1 and LQT2 women^*

MENOPAUSAL PHASE†	LQT1 WOMEN		LQT2 WOMEN
	Hazard Ratio (95% Confidence Interval)	P value	Hazard Ratio (95% Confidence Interval)	P value
Post-menopause vs. pre-menopause risk by treatment with estrogen therapy†
Post-menopause without estrogen HRT vs. reproductive period	0.20 (0.02 - 2.08)	0.18	7.73 (2.22 - 26.93)	<0.001
Post-menopause with estrogen HRT vs. reproductive period	0.46 (0.07 - 3.07)	0.42	5.10 (1.62-15.97)	<0.001
Beta-blocker effect†
Beta-blocker- vs, no beta-blocker-therapy	0.40 (0.17 - 0.87)	0.02	0.51 (0.29 - 0.89)	0.02

^*Multivariate analysis was carried out using combined PWP and Anderson-Gill modeling, with the menopausal periods and therapies assessed as time-dependent covariates in the multivariate models; findings are adjusted time-dependent beta-blocker therapy and QTc (assessed as a continuous measure); similar results were obtained in a secondary analysis that included further adjustment for time-dependent comorbidities (including diabetes mellitus, smoking status, prior myocardial infarction, and the presence of angina pectoris).

^†Estrogen therapy during the postmenopausal phase was assessed as a time-dependent covariate; the effects of progesterone therapy and of estrogen therapy during the transitional phases were not assessed due to sample size limitations.